Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate, CRS3123 to Treat C. difficile infection.
Learn More:
Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial of Novel Antibiotic Candidate, CRS3123 to Treat C. difficile infection.
Learn More: